Everolimus and fulvestrant is another standard-of-care option, and with the evidence from this trial, I won’t have to fight insurance companies for reimbursement.— Virginia Kaklamani, MD
How can the results of this trial be applied to clinical practice? Press conference moderator, Virginia Kaklamani, MD, of the University of Texas Health Science Center in San Antonio, said: “The landscape has changed. Now we treat postmenopausal hormone receptor–positive, HER2-negative metastatic breast cancer with letrozole and palbociclib [Ibrance] first line. What do we do for second-line therapy? We would not use another aromatase inhibitor. We could use fulvestrant [Faslodex] or exemestane plus everolimus [Afinitor].”
“This study suggests that everolimus and fulvestrant is a new option for second-line therapy. It is another standard-of-care option, and with the evidence from this trial, I won’t have to fight insurance companies for reimbursement,” Dr. Kaklamani said. ■
Disclosure: Dr. Kaklamani reported no potential conflicts of interest.
The addition of everolimus (Afinitor) to fulvestrant (Faslodex) doubled progression-free survival in postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer resistant to aromatase inhibitor therapy compared with fulvestrant plus placebo, according to the...